遗传或基因组检测评估报告的范围综述揭示临床效用关键维度的考量不一致
该范围综述检索了多个数据库和灰色文献,最终纳入57份遗传或基因组检测评估报告,提取951个疾病特异性指标,并按十个临床效用维度分析。最常评估的维度为临床有效性(79%)、临床效能(79%)、分析有效性(60%)和经济影响(58%);仅12份评估比较了检测组与未检测组的健康结局,不足15%的评估涉及公平性、可接受性、合法性和个人价值。
要点
- 最常评估的维度为临床有效性(79%)、临床效能(79%)、分析有效性(60%)和经济影响(58%)。
- 仅12份评估比较了检测组与未检测组的健康结局。
- 不足15%的评估涉及公平性、可接受性、合法性和个人价值。
核心结论
- 研究显示,尽管公平性和可接受性等维度在传统评估框架中受到显著强调,但这些维度在评估中常未被考虑。
- 研究凸显了关于这些检测临床效能的已报告原始证据严重缺乏。
研究设计与样本
- 研究为范围综述,检索PubMed、Web of Science、Scopus、20个不同组织网站、Google和Google Scholar,评估用于预防的遗传和基因组检测评估报告。
- 共审查3054条唯一参考文献和12000条灰色文献检索结果,最终纳入57份评估报告。
主要发现
- 使用的参考框架为卫生技术评估(HTA)(42%)、基因组应用实践与预防评估(EGAPP)(25%)、ACCE(21%)和其他(12%)。
- 共识别951个疾病特异性指标。
- 最常评估的维度为分析有效性(60%)、临床有效性(79%)、临床效能(79%)和经济影响(58%)。
- 仅12份评估比较了检测组与未检测组的健康结局。
- 不足15%的评估涉及公平性、可接受性、合法性和个人价值。
关键数值与推荐
- 从951个疾病特异性指标中提炼出一份约150个通用指标的列表。
- 指标按十个综合临床效用维度、所用评估框架和指标类型(定量、定性、参考或无证据报告)分层分析。
临床怎么用
- 作者指出,简化的约150个通用指标列表可帮助检测开发者决定研究哪些因素、评估者确定测量什么、政策制定者在决定是否采纳检测前识别可能缺失的内容。
- 作者指出,若不考虑公平性、患者偏好和已证实的健康获益等问题,可能投资于获益甚微甚至伤害患者的检测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Genetic and genomic tests are the cornerstone of personalized preventive approaches. Inconsistency in evaluating their clinical utility is often cited as a reason for their limited implementation in clinical practice. Previous reviews have primarily focused on theoretical frameworks used for clinical utility evaluations of genetic tests, rather than actual assessments and examined dimensions, rather than specific indicators within these dimensions. We aimed to review the dimensions and the specific indicators measured in published assessment reports of genetic or genomic tests. STUDY DESIGN AND SETTING: We conducted a scoping review of assessment reports of genetic and genomic tests used for prevention, searching through PubMed, Web of Science, Scopus, the websites of 20 different organizations, Google, and Google Scholar. From the included assessments, we extracted the reported indicators of clinical utility, compiling a list of disease-specific indicators that detailed their numerator, denominator, and calculation methods. We analyzed the extracted indicators by stratifying them according to ten comprehensive dimensions of clinical utility, the assessment framework used, and the type of indicator (categorized as quantitative, qualitative, reference, or no evidence reported). From these indicators, we then distilled a list of general indicators. RESULTS: We reviewed 3054 unique references and 12,000 results from gray literature searches, ultimately selecting 57 assessment reports. The reference frameworks used were health technology assessment (HTA) (42%), Evaluation of Genomic Applications in Practice and Prevention (EGAPP) (25%), ACCE (21%), and others (12%). We identified 951 disease-specific indicators. The dimensions most frequently evaluated (ie, had at least one indicator) were analytic validity (60%), clinical validity (79%), clinical efficacy (79%), and economic impact (58%). Only 12 assessments compared health outcomes between tested and untested groups, and fewer than 15% of the assessments addressed equity, acceptability, legitimacy, and personal value. CONCLUSION: Our study illustrates that, although dimensions such as equity and acceptability, are significantly emphasized in traditional evaluation frameworks, these are often not considered in the assessments. Additionally, our study has underscored a significant dearth of reported primary evidence concerning the clinical efficacy of these tests. PLAIN LANGUAGE SUMMARY: Genetic and genomic tests analyze a person's genes to predict health risks and guide healthcare decisions, potentially identifying who might benefit from certain treatments or check-ups. However, determining whether these tests are genuinely useful for wide use in health services is complex, because there is no standard way to define "clinical utility" of a genetic test. To understand how these tests are evaluated, we reviewed 57 evaluation reports from high-income countries, most of which focused on cancer-related genetic tests. We found that many evaluations looked mainly at how well a test predicted a condition (validity) and considered some form of effectiveness, yet often failed to measure whether the test truly improved patient health outcomes, such as lowering death rates or enhancing the quality of life. Moreover, factors like patient acceptance, equity, and personal relevance (eg, reducing anxiety) were frequently overlooked. Without including these broader considerations, evaluations risk missing critical evidence that would indicate whether a test is helpful, fair, and worth using. From over 900 unique indicators used to measure clinical utility, we created a simpler list of about 150 general indicators that can guide future evaluations. This consolidated list can help test developers decide which factors to investigate, evaluators determine what to measure, and policymakers identify what might be missing before deciding if a test should be adopted in healthcare. By highlighting the gaps-areas that should be assessed but currently are not-our study encourages a more comprehensive approach to evaluating genetic tests. If we fail to consider issues like equity, patient preferences, and proven health benefits, we risk investing in tests that may do little good or even harm patients. Ultimately, recognizing these shortcomings can lead to better-informed decisions, ensuring that genetic testing is used in ways that truly benefit patients and deliver safer, more personalized, and fairer healthcare for everyone.
引用
- Pezzullo AM, Valz Gris A, Scarsi N, et al. A scoping review of the assessment reports of genetic or genomic tests reveals inconsistent consideration of key dimensions of clinical utility. J Clin Epidemiol. 2025. PMID: 39986491. doi:10.1016/j.jclinepi.2025.111729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。